MedPage Today (3/24, Henderson) reports a systematic scoping review of 12 articles suggests that consumers should not “expect accuracy and transparency in the promotion of prescription drugs by social media influencers.” While evidence was limited in the review, researchers observed that “recurrent themes in posts about prescription drugs by influencers included misinformation and blurred lines between personal testimony and paid promotion, with weak regulatory oversight.” Of the review’s findings, “concerns about accuracy and misinformation were raised in seven studies.” In addition, the authors wrote that several studies detailed the “critical role of parasocial dynamics in shaping trust and engagement with influencer content (persuasiveness).” Furthermore, researchers noted that FDA and FTC guidance on transparency was “described as vague, outdated, and difficult to enforce across global platforms.” The review was published in JAMA Network Open.
Related Links:
— MedPage Today (requires login and subscription)